KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc., today announces its HARTTM AS multi-protein, artificial intelligence (AI)-driven test, which data indicates accurately diagnoses Aortic Stenosis (AS)—a condition with a 50 percent death rate when left untreated.
AS is the most common valvular heart disease in the Western world, present in more than 20 percent of older adults. The condition occurs when the heart’s aortic valve narrows, which frequently occurs with aging. This narrowing prevents the valve from opening fully, which reduces or blocks blood flow from the heart into the aorta. Left untreated, AS can lead to adverse cardiac events, including heart failure and death.
HART AS identifies the presence of AS and predicts the need for future medical intervention. Researchers believe the data, to be presented on March 12 at American College of Cardiology 2018 Scientific Sessions, can assist patients in getting guideline-recommended serial evaluations proven to enhance health outcomes. It could also lead to the use of this test as a more widely available, less expensive, and more accurate test than echocardiography, otherwise known as ultrasounds of the heart.
“The HART AS blood test holds significant promise for earlier diagnosis and treatment of many more patients with aortic stenosis,” said James L. Januzzi, MD, practicing cardiologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Januzzi served as Principal Investigator on the team of researchers that conducted the study. They found that when patients were divided into low-risk and high-risk categories, the test predicted with 98 percent accuracy to exclude severe AS.
“There are several inconsistencies with echocardiographic assessment that can hinder timely clinical decisions,” Januzzi added. “With the increasing use of minimally invasive aortic valve replacement, HART AS is well-positioned to assist in providing more appropriate care of patients.”
“In the U.S. alone, more than five million Americans are diagnosed with heart valve disease each year,” stated Rhonda Rhyne, Prevencio’s Chief Executive Officer. “Prevencio’s HART AS is a critical diagnostic and monitoring solution to assist in the care of AS patients.”
Rhyne added, “We appreciate our collaboration with Massachusetts General Hospital, Dr. Januzzi and his researchers, and Myriad RBM to develop innovative and highly accurate blood tests to improve diagnosis and treatment for millions of cardiovascular patients. We look forward to working with medical device companies involved with minimally invasive valve replacement, including Medtronic, Edwards Lifesciences and Abbott Vascular, to better identify patients who would benefit from interventional treatment.”
Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease. Employing this novel approach, the company has produced five blood tests to-date that significantly improve diagnoses for a variety of heart and blood vessel-related complications.
These tests are:
1. HART CADTM – obstructive coronary artery disease diagnosis
2. HART CVETM – 1-year risk of heart attack, stroke or cardiac death
3. HART PADTM – peripheral artery disease diagnosis
4. HART ASTM – aortic valve stenosis
5. HART AMPTM – risk of amputation
HART test results have been presented at leading cardiovascular meetings (European Society of Cardiology Congress Scientific Sessions – 2016, American College of Cardiology Scientific Sessions – 2017, American Heart Association Scientific Sessions – 2017, American College of Cardiology Scientific Sessions – 2018) and published in top-tier cardiology journals (Journal of American College of Cardiology – March 2017 and American Journal of Cardiology – July 2017).
About Prevencio, Inc.:
Prevencio’s mission is to prevent the preventable – improving patient outcomes and reducing healthcare costs by preventing unnecessary cardiovascular procedures and procedure-related side effects, as well as predicting — and hopefully thereby preventing — one year adverse cardiovascular events. The company is a pioneer in diagnostic and predictive tests for cardiovascular disease and related adverse events, as well as for cardiovascular pharmaceutical research. Prevencio’s proprietary HART™ Tests are leading the way in the proteomics and artificial intelligence era of improving cardiovascular medical care. The company is headquartered in Kirkland, Washington. For additional information on Prevencio, visit www.PrevencioMed.com. Prevencio—Preventing the Preventable.™
About American College of Cardiology (ACC):
The American College of Cardiology has a membership of 52,000 cardiovascular professionals dedicated to transforming cardiovascular care and improving heart health.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, size, potential, and penetration rates, the accuracy of which is necessarily subject to uncertainties and risks including the Company’s sole dependence on HART technology and various uncertainties characteristic of development-stage companies. The Company does not undertake to update the disclosures contained in this press release.